Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Selecta Biosciences revenue
Selecta Biosciences's revenue is $38.9 million.
What is Selecta Biosciences's revenue?
- Selecta Biosciences peak revenue was $110.8M in 2022.
- Selecta Biosciences annual revenue for 2023 was 26.0M, -76.53% growth from 2022.
- Selecta Biosciences annual revenue for 2024 was 38.9M, 49.64% growth from 2023.
- Selecta Biosciences's revenue growth from 2017 to 2024 is 18,698.55%.
- Selecta Biosciences has 39 employees, and the revenue per employee ratio is $997,769.
- Selecta Biosciences's peak quarterly revenue was $39.3M in 2022(q2).
On this page
Zippi applies for you, and finds you a job.
Selecta Biosciences historical revenue
Selecta Biosciences's peak revenue was $110.8M in 2022. The peak quarterly revenue was $39.3M in 2022(q2).
Selecta Biosciences's revenue increased from $6.0m in 2017 to $38.9M currently. That's a 18,698.55% change in annual revenue.
Selecta Biosciences annual revenue
Selecta Biosciences annual revenue over time
| Fiscal year / year | Selecta Biosciences revenue |
|---|---|
| 2017 | $207,000 |
| 2018 | $903,000 |
| 2019 | $6.7M |
| 2020 | $16.6M |
| 2021 | $85.1M |
| 2022 | $110.8M |
| 2023 | $26.0M |
| 2024 | $38.9M |
How accurately did Selecta Biosciences' revenue projections match actual performance?
Selecta Biosciences annual growth
Selecta Biosciences saw the greatest revenue growth in 2019, when revenue increased by 639.42%.
Selecta Biosciences had the lowest revenue growth in 2017, when revenue changed by -97.44%.
Selecta Biosciences annual growth rate over time
| Year | Selecta Biosciences growth |
|---|---|
| 2018 | 336%↑ |
| 2019 | 639%↑ |
| 2020 | 149%↑ |
| 2021 | 413%↑ |
| 2022 | 30%↑ |
| 2023 | -77%↓ |
| 2024 | 50%↑ |
Selecta Biosciences quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Selecta Biosciences quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | $10,000 | $13,000 | - | $6.7M |
| 2020 | - | - | $4.6M | $12.0M |
| 2021 | $11.1M | $19.7M | $24.4M | $29.9M |
| 2022 | $34.0M | $39.3M | $20.7M | $16.8M |
| 2023 | $5.9M | $5.2M | $6.6M | $8.3M |
| 2024 | $5.8M | $33.4M | $387,000 | ($759.0K) |
Selecta Biosciences jobs nearby
Do you work at Selecta Biosciences?
Did Selecta Biosciences meet its revenue projections?
Selecta Biosciences financial information
| CEO | Carsten Brunn |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 39 |
| Date Founded | 2007 |
| Headquarters | Watertown Town, Massachusetts |
| Number of Locations | 1 |
| Revenue | $38.9M |
| Net Income | $35,379,000 |
| Tax Rate | -0.0% |
| Total Assets | $165,886,000 |
| Ticker | SELB |
Selecta Biosciences jobs you might like
Selecta Biosciences financing
Selecta Biosciences received early financing of $2.5M on 2008-05-01.
| Series | Round size | Date |
|---|---|---|
| Seed | $2.5M | 05/2008 |
| Series B | $15.1M | 02/2009 |
| Series C | $15M | 04/2010 |
| Grant | $3M | 08/2010 |
| Series D | $47.3M | 10/2011 |
| Series D | $22M | 02/2012 |
| Series Unknown | $5.3M | 04/2014 |
| Grant | $8.1M | 06/2014 |
| Series Unknown | $4.5M | 08/2014 |
| Private Equity | $20M | 10/2014 |
| Grant | $3.2M | 12/2014 |
| Series Unknown | $5.9M | 04/2015 |
| Series E | $38M | 09/2015 |
| Post Ipo Equity | $5.0M | 12/2016 |
| Post Ipo Equity | $21M | 09/2017 |
| Post Ipo Equity | $5.8M | 08/2019 |
| Post Ipo Equity | $25M | 08/2020 |
| Post Ipo Debt | $35M | 09/2020 |
| Post Ipo Equity | $38.7M | 04/2022 |
Selecta Biosciences investors
| Investors | Security type |
|---|---|
| Polaris Venture Capital | Seed |
| Flagship Pioneering Inc | Seed |
| Polaris Partners | Series B |
| Timothy A. Springer | Series B |
| NanoDimension | Series B |
| Flagship Pioneering Inc | Series B |
| Polaris Partners | Series C |
| LEUKON INVESTMENTS LP | Series C |
| OrbiMed Advisors | Series C |
| NanoDimension | Series C |
| Flagship Pioneering Inc | Series C |
| National Institutes of Health (NIH) | Grant |
| Rusnano | Series D |
| Rusnano | Series D |
| Polaris Partners | Private Equity |
| Eminent Venture Capital | Private Equity |
| Rusnano | Private Equity |
| LEUKON INVESTMENTS LP | Private Equity |
| OrbiMed Advisors | Private Equity |
| NanoDimension | Private Equity |
| Flagship Pioneering Inc | Private Equity |
| I2BF Global Ventures | Private Equity |
| Skolkovo Foundation | Grant |
| Polaris Partners | Series E |
| Aju IB Investment | Series E |
| Sphera Fund | Series E |
| LEUKON INVESTMENTS LP | Series E |
| Rusnano | Series E |
| NanoDimension | Series E |
| I2BF Global Ventures | Series E |
| Ridgeback Capital | Series E |
| Eminent Venture Capital | Series E |
| Osage University Partners | Series E |
| Sanofi Ventures | Series E |
| OrbiMed Advisors | Series E |
| Scott H. Cohen | Series E |
| Flagship Pioneering Inc | Series E |
| Osage University Partners | Post Ipo Equity |
| Oxford Finance LLC | Post Ipo Debt |
| Silicon Valley Bank | Post Ipo Debt |
Selecta Biosciences competitors
Selecta Biosciences's top competitor, Sarepta Therapeutics, earned an annual revenue of $1.9B.
Selecta Biosciences's smallest competitor is GT Biopharma with revenue of $27.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Ziopharm oncology | - | $6.4M | 48 | - |
| Sarepta Therapeutics | - | $1.9B | 840 | - |
| Zafgen | - | $6.5M | 20 | - |
| Asklepios BioPharmaceutical | - | $115.0M | 820 | - |
| GT Biopharma | - | $27,000 | 2 | - |
| Talaris Therapeutics | - | $119.6M | 30 | - |
| PTC Therapeutics | - | $806.8M | 517 | - |
| Constellation Pharmaceuticals | - | $4.7M | 82 | - |
| Acceleron Pharma | - | $92.5M | 312 | - |
| Genocea | - | - | 59 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Selecta Biosciences highest paying jobs
Zippia gives an in-depth look into the details of Selecta Biosciences, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Selecta Biosciences. The employee data is based on information from people who have self-reported their past or current employments at Selecta Biosciences. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Selecta Biosciences. The data presented on this page does not represent the view of Selecta Biosciences and its employees or that of Zippia.
Selecta Biosciences may also be known as or be related to SELECTA BIOSCIENCES INC, Selecta Biosciences, Selecta Biosciences Inc and Selecta Biosciences, Inc.